NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, including orphan diseases, infectious diseases and metabolic diseases, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020, 10:00 a.m. ET. Aptorum Group’s President and Executive Director Mr. Darren Lui will join a panel, which entitled “Non-antibiotic Anti-infectives.” This panel is scheduled for 10:30 a.m. ET to 12:00 p.m. ET. To RSVP for the virtual conference, please click through: https://m-vest.com/insights/blog/Infectious-Disease-Virtual-Conference-2020
To access the live presentation, please use the following information:
Maxim Group’s Infectious Disease Virtual Conference
Date: Tuesday, May 5, 2020
Time: 10:00 AM Eastern Time (7:00 AM Pacific Time)
Panel Session Title: Non-antibiotic Anti-infectives
Date: Tuesday, May 5, 2020
Time: 10:30 AM Eastern Time (7:30 AM Pacific Time)
If you would like to book 1 on 1 investor meetings with Aptorum Group, please make sure you are registered for the virtual event here:
http://m-vest.com/signup
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group's current drug pipeline include indications in orphan diseases, infectious diseases and metabolic diseases and a number of which are targeted to enter clinical trial phases in 2020. Aptorum Group’s Dioscorea Opposita Bioactive Nutraceutical Tablets, which is a dietary supplement for women’s health during menopause and post-menopause cycles, are currently being commercialized.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
